Schizophrenia Clinical Trial
Official title:
Influence of Nicotine on Cognitive Function in Schizophrenic Patients With and Without Comorbid Drug Dependence
Background:
- Individuals with schizophrenia have a significantly higher tendency to develop substance
abuse or dependence than the general population. For instance, people with schizophrenia
smoke much more than the general population, and many are dependent on street drugs such
as cocaine and heroin. However, these individuals are rarely included in research
studies that might provide more information about treatments for both schizophrenia and
substance abuse.
- Strong evidence suggests that schizophrenia and substance dependence have similar
effects on the brain, affecting attention, memory, and eye movement. Other research
indicates that schizophrenia and substance dependence affect the same parts of the
dopamine system, contributing to problems in brain function that require treatment.
These new developments provide a strong rationale to study the combination of
schizophrenia and substance dependence.
- Nicotine may help improve brain function and thinking in individuals with both
schizophrenia and drug dependence. Some of the thinking and memory problems experienced
by these individuals can be treated with nicotine. However, more research is needed to
determine exactly how nicotine affects individuals with both schizophrenia and drug
dependence.
Objectives:
- To determine whether individuals with schizophrenia and drug dependence show impairment
in tests of eye tracking, attention, and memory compared with healthy control subjects.
- To evaluate the effect of nicotine on eye tracking, attention, and memory in individuals
with both schizophrenia and substance dependence.
Eligibility:
- Current smokers (at least 10 cigarettes per day for the past year) between 18 and 55 years
of age who (1) have been diagnosed with schizophrenia/schizoaffective disorder, (2) have been
diagnosed with schizophrenia/schizoaffective disorder and are currently using heroin and/or
cocaine, or (3) are healthy individuals with no family history of psychotic illness.
Design:
- The study will consist of one training session and three testing sessions. Each session
will last about 2 hours.
- The training session will introduce participants to the study tests and evaluate their
tolerance of the nicotine nasal spray used in the study. Participants who cannot
tolerate the higher dose of the spray will not continue in the study.
- At the start of each testing session, smokers will have one cigarette to standardize the
time of the most recent exposure to nicotine.
- During the testing sessions, participants will receive a placebo spray, a lower dose of
nicotine, or a higher dose of nicotine, and then will be asked to perform tests that
evaluate attention, memory, and other thinking tasks.
Objective:
Specific aim 1: To test the hypothesis that individuals with comorbid schizophrenia and drug
dependence will show impaired neurocognitive functions in anticipatory learning of
eyetracking, attention, and memory performance compared to healthy controls subjects.
Specific aim 2: To test the hypothesis that nicotine will dose-dependently improve
anticipatory learning of eyetracking, attention, and memory performance in individuals with
comorbid schizophrenia and substance dependence.
Study Population:
Male and nonpregnant-female smokers 18 to 55 years of age, from the following subject groups:
(1) patients with a DSM IV diagnosis of schizophrenia (2) patients with dual DSM IV diagnoses
of schizophrenia and heroin and/or cocaine dependence or abuse, or on methadone or
beprenorphine maintenance and (3) healthy individuals with no family history of psychotic
illness.
Design:
This study will be a double-blind, placebo controlled trial of nicotine or placebo nasal
sprays. Participants will have four visits. After the training session, participants will be
administered one dose (0, 1 or 2 mg) of nicotine nasal spray during each of the 3
experimental sessions. The dose will be given 5 minutes prior to the cognitive task
batteries.
Outcome Measures:
Vital signs, moods, and performance on tasks assessing eye movement (initiation latency,
initiation acceleration, closed-loop pursuit gain), attention (Continuous Performance and
Digit Symbol Substitution Tasks), and memory (delayed recognition and nback).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |